Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- multiple myeloma (3)
- amplicon sequencing (2)
- cell staining (2)
- AKT-signaling (1)
- Activation (1)
- Antibodies (1)
- B cells (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantation (1)
- CD319 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- Cancer treatment (1)
- Fak regulation (1)
- GvHD (1)
- HD (1)
- IRF4 (1)
- Induced apoptosis (1)
- KRAS (1)
- Lymphomas (1)
- MEK/ERK-signaling (1)
- MTB (1)
- MTX (1)
- Mechanisms (1)
- Medizin (1)
- Migration (1)
- Multiple (1)
- Myeloma cells (1)
- Myelomas (1)
- NF-Kappa-B (1)
- NFAT (1)
- Pathogenesis (1)
- Phase- (1)
- Positron emission tomography (1)
- R-CHOP (1)
- Spleen (1)
- Stromal cells (1)
- T cells (1)
- T-cell transfer (1)
- Th17 (1)
- Tregs (1)
- actin (1)
- acute graft-versus host disease (1)
- acute myeloid leukaemia (1)
- alloreactive T cells (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- antigen loss (1)
- apoptosis (1)
- biosynthesis (1)
- bone marrow cells (1)
- brain tumor (1)
- cancer care (1)
- cancer metabolism (1)
- cancer stem cells (1)
- cell binding (1)
- cell death (1)
- children (1)
- complement system (1)
- cytotoxicity (1)
- enzyme-linked immunoassays (1)
- extramedullary disease (1)
- gRNA-only (1)
- glioblastoma (1)
- group 3 (1)
- immunohistochemistry techniques (1)
- immunotherapeutics (1)
- inflammation-induced tissue demage (1)
- kidney cancer (1)
- lesions (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphoma (1)
- mTOR (1)
- machine learning (1)
- mantle cell lymphoma (1)
- mesenteric lymph node (1)
- metabolism (1)
- methylation (1)
- mitochondrial DNA (1)
- monoclonal antibody (1)
- mouse models (1)
- mtDNA (1)
- naive T-cell gene editing (1)
- obinutuzumab (1)
- organoids (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- pan-RCC (1)
- patient access (1)
- plasma cells (1)
- precision oncology (1)
- rare SNP (1)
- real world data (1)
- receptor tyrosine kinases (1)
- slice culture (1)
- suppression (1)
- systemic sclerosis (1)
- target validation (1)
- targeted therapies (1)
- tumormicroenvironment (1)
- venetoclax (1)
Institute
- Medizinische Klinik und Poliklinik II (20) (remove)
Sonstige beteiligte Institutionen
While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.